https://www.selleckchem.com/pr....oducts/skf38393-hcl.
en though they decreased over time. All differences in active treatment rates according to race/ethnicity depend on baseline patient and tumor characteristics. There are limited data to support the safety of active surveillance in men with favorable-intermediate risk prostate cancer due only to a prostate specific antigen (PSA) above 10 ng/ml. We therefore evaluated the impact of pretreatment PSA on risk-stratification in men with Gleason 6 prostate cancer. We identified men aged 18 to 75 with cT1-2cN0cM0, pre-treatment PSA 20
Curtir
Comentario
Compartilhar
